Learn about randomized controlled trial results and supporting data for Boston Scientific's Eluvia Drug-Eluting Stent.

Sep 18, 2018 · Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued …

The results of the EMINENT study show a significantly higher patency of the Eluvia® DES compared to BMSs for the treatment of FP lesions, supporting the advantage of drug eluting polymers for an …

Sep 6, 2016 · The EMINENT study is a prospective, multi-center study evaluating the effectiveness of the ELUVIA stent versus Self-Expanding Bare Nitinol Stents in the treatment of lesions in the …

Oct 18, 2022 · By demonstrating superior 1-year primary patency, the results of the EMINENT randomized study support the benefit of using a polymer-based paclitaxel-eluting stent as a first-line …

Oct 12, 2021 · A drug-eluting stent is a better choice for treating superficial femoral and proximal popliteal lesions in terms of sustained efficacy in comparison with a BMS, according to 1-year results …

This review examines the safety and efficacy of drug-coated devices in the endovascular treatment of peripheral arterial disease.

The EMINENT trial is the largest randomised controlled trial (RCT) comparing Eluvia™ Drug-Eluting Stent System to self-expanding bare metal stents (BMS).

Jan 28, 2024 · Among the treatment modalities for PAD, different DESs showed overall encouraging results in terms of PP and TLR compared with BMSs. DES-Evero 1 ug/mm2 showed the best primary …

JACC Cardiovasc Interv. 2021;10:1123–1133. 2. Gouëffic Y, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the …